where to next?, page-1169

All MC practically get a mention but below is AC8's if interested

https://smallcaps.com.au/cannabis-stocks-asx-ultimate-guide/

Cannabinoid pharmaceutical company AusCann Group is focused on developing and producing capsule-based pharmaceutical products for the management of chronic pain including neuropathic pain.

In January 2019, the company finalised the purchase of a research and development facility in Perth, Western Australia, which it said completed its previously announced long-term development strategy.

The facility, which will undergo a planned upgrade, will be used to progress AusCann’s pharmaceutical product pipeline. This includes the impending production of hard-shell cannabinoid capsules, which are set to be released for clinical trials towards mid-2019.

AusCann has multiple divisions under its umbrella and has secured several partnerships across the supply chain from raw materials, product development to manufacturing and sales.

It is partnered with Canada’s largest medicinal cannabis group Canopy Growth Corporation and European cannabis breeding company Phytoplant.

It also has an agreement with MediPharm Labs to supply cannabis resin to use in AusCann’s hard shell capsules and is jointly establishing cannabis cultivation, manufacturing and distribution operations in Tasmania with opium poppy exporter Tasmanian Alkaloids.

In addition, its Chilean joint venture company DayaCann inked a non-binding memorandum of understanding late last year with Canadian company Khiron Life Sciences (TSXV: KHRN) to supply medical cannabis products for patients in Chile.

The company also has a distribution agreement in place with Australian Pharmaceutical Industries (ASX: API), Australia’s largest pharmaceutical distributor with brands including Priceline and Soul Pattinson Chemist.